Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||HRAS G12S|
|Indication/Tumor Type||head and neck squamous cell carcinoma|
|Response Type||predicted - sensitive|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|HRAS G12S||head and neck squamous cell carcinoma||predicted - sensitive||Tipifarnib||Preclinical - Pdx||Actionable||In a preclinical study, a head and neck squamous cell carcinoma patient-derived xenograft (PDX) model harboring HRAS G12S was sensitive to treatment with Zarnestra (tipifarnib), demonstrating inhibition of tumor growth, decreased cell proliferation, and reduced Erk activity (PMID: 32727882).||32727882|
|PubMed Id||Reference Title||Details|
|(32727882)||Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas.||Full reference...|